The Global biologics market was valued at $317.2 billion in 2022 and is expected to reach $669.0 billion by 2030, growing at a CAGR of 9.5% from 2022 to 2030.

The market growth can be attributed to factors such as increasing prevalence of chronic diseases, advancements in biotechnology, and growing demand for personalized medicine.

The global biologics market refers to the market for biopharmaceuticals, which are drugs made from biological sources such as living cells and organisms. Biologics are used to treat a wide range of medical conditions, including cancer, autoimmune disorders, and infectious diseases.

Some of the major players in the biologics market include Amgen, Roche, Johnson & Johnson, Novartis, AbbVie, Bristol-Myers Squibb, and Pfizer. These companies are investing heavily in research and development to introduce new and innovative biologics that can address unmet medical needs and improve patient outcomes.

Market Dynamics

Driving Factors

The global biologics market is being driven by several key factors, including:

Growing demand for personalized medicine: Biologics are increasingly being used in personalized medicine, which involves tailoring treatment to the individual patient based on their genetic makeup and other factors. Biologics are well-suited for this approach due to their targeted mechanism of action.

Increasing healthcare spending: Healthcare spending is increasing globally, driven by factors such as population growth, aging populations, and the rising cost of healthcare. Biologics are often more expensive than traditional drugs, but their effectiveness and safety justify their cost in many cases.

Favorable regulatory environment: Governments around the world are supporting the development and commercialization of biologics through favorable regulatory environments and funding for research and development. This has encouraged pharmaceutical companies to invest in biologics and bring new treatments to market.

Restraining Factors

The global biologics market also faces some restraining factors, including:

Competition from biosimilars: Biosimilars are drugs that are highly similar to existing biologics and are approved for the same indications. Biosimilars are generally cheaper than the original biologics, and their increasing availability can lead to pricing pressure for the original biologics.

Manufacturing complexities: Biologics are more complex to manufacture than traditional drugs, and the process requires highly specialized facilities and equipment. This can be a barrier to entry for smaller companies and can also limit the availability of biologics in certain regions.

Intellectual property concerns: Biologics are often protected by patents, which can limit competition and keep prices high. However, when these patents expire, it can lead to increased competition from biosimilars and lower prices for consumers.

Challenges Factors

The biodegradable plastics market faces several challenges, including:

Certification and standardization: There is currently no widely recognized standard for biodegradable plastics, which can make it difficult for businesses and consumers to know which products are truly environmentally friendly. Certification programs can help to address this challenge, but there is still a lack of standardization across the industry.

Disposal infrastructure: Biodegradable plastics require specialized disposal infrastructure to ensure they break down properly in the environment. In many areas, this infrastructure is not widely available, which can limit the adoption of biodegradable plastics.

Price competitiveness: Biodegradable plastics are generally more expensive than traditional plastics, which can make it difficult for them to compete on price. In some cases, businesses and consumers may be unwilling to pay a premium for environmentally friendly products.

Opportunity Factors

The global biologics market offers several opportunities for growth and innovation, including:

Personalized medicine: Personalized medicine, which involves tailoring treatment to the individual patient based on their genetic makeup and other factors, is a growing trend in healthcare. Biologics are well-suited for this approach, and there is an opportunity to develop new biologics that can be used in personalized medicine.

Collaboration and partnerships: Collaboration and partnerships between pharmaceutical companies, biotech firms, and research institutions can help drive innovation and accelerate the development of new biologics. These collaborations can also help address manufacturing complexities and regulatory challenges.

Digital technologies: The integration of digital technologies such as artificial intelligence, machine learning, and big data analytics into drug development and manufacturing can help improve efficiency, reduce costs, and accelerate the development of new biologics. These technologies can also be used to improve patient outcomes and personalize treatment.

Segmentation Analysis

Product Outlook

Monoclonal antibodies (mAbs) are the largest product segment in the biologics market. They are used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. Examples of mAbs include Rituxan, Humira, and Keytruda.

Vaccines are another important product segment in the biologics market. They are used to prevent infectious diseases and are often administered to healthy individuals. Examples of vaccines include the COVID-19 vaccines, as well as vaccines for measles, mumps, and rubella.

Recombinant proteins are proteins that are produced through genetic engineering. They are used to treat a variety of medical conditions, including hemophilia, diabetes, and growth disorders. Examples of recombinant proteins include insulin, erythropoietin, and factor VIII.

Disease Outlook

Cancer is the largest disease category segment in the biologics market. Biologics are used to treat various types of cancer, including breast cancer, lung cancer, and leukemia. Monoclonal antibodies such as Herceptin, Avastin, and Rituxan are commonly used to treat cancer.

Autoimmune disorders such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis are another major disease category segment in the biologics market. Biologics are used to suppress the immune system and reduce inflammation. Examples of biologics used to treat autoimmune disorders include Humira, Enbrel, and Remicade.

Infectious diseases such as HIV/AIDS, hepatitis, and influenza are another important disease category segment in the biologics market. Biologics are used to stimulate the immune system and fight infections. Examples of biologics used to treat infectious diseases include the COVID-19 vaccines, as well as vaccines for hepatitis B and C.

Rare diseases such as cystic fibrosis, hemophilia, and Pompe disease are a growing disease category segment in the biologics market. Biologics are used to treat or cure these diseases by replacing or repairing defective genes or proteins. Examples of biologics used to treat rare diseases include Spinraza and Zolgensma.

Regional Analysis

North America is the largest market for biologics, accounting for a significant share of the global market. The United States is the largest market in the region, with a large and well-established biotechnology industry. Canada is also an important market for biologics.

Europe is the second-largest market for biologics, with countries such as Germany, France, and the United Kingdom being major players in the market. The European Union has a well-established regulatory framework for biologics, which has helped to support the growth of the market.

Scope Of Report:

The Global Biologics Market has been segmented into:

By Product

Monoclonal Antibodies

• Diagnostic
• Biochemical Analysis
• Diagnostic Imaging
• Therapeutic
• Direct MAB Agents
• Targeting MAB Agents
• Protein Purification
• Others

MABs by type

• Murine
• Chimeric
• Humanized
• Human
• Others

Vaccines

• Recombinant Proteins
• Antisense, RNAi, & Molecular Therapy
• Others

By Disease Category

• MABs
• Antisense, RNAi, & Molecular Therapy
• Recombinant Proteins
• Others

Immunological Disorders

• Cardiovascular Disorders
• Hematological Disorders
• Others

By Biologics Manufacturing

• Outsourced
• In-house

By Region

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Market Players 

The global biologics plastic market is highly competitive and fragmented, with numerous players vying for market share. Some of the key companies in the market are:

• Samsung BioLogics
• Amgen; Novo Nordisk A/S
• AbbVie Inc.
• Sanofi
• Johnson & Johnson Services, Inc
• Pfizer Inc.
• Merck & Co.
• GSK group of companies
• Celltrion 
• Precision Biologics, Inc.
• Merck KGaA
• Eli Lilly and Company
• Novartis AG
• Bayer AG
• F. Hoffmann-La Roche Ltd
• AstraZeneca

Roche is a Swiss multinational healthcare company that is a major player in the biologics market. The company is a leading manufacturer of biologic drugs such as Herceptin, Avastin, and Rituxan.

Amgen is a US-based biotechnology company that develops and manufactures biologic drugs for the treatment of cancer, autoimmune diseases, and other conditions. Some of its major biologic products include Enbrel, Neulasta, and Epogen.

AbbVie is a US-based pharmaceutical company that specializes in the development and manufacture of biologic drugs for the treatment of autoimmune diseases, cancer, and other conditions. Some of its major biologic products include Humira, Imbruvica, and Venclexta.

Novo Nordisk is a Danish multinational pharmaceutical company that is a major player in the biologics market. The company specializes in the development and manufacture of biologic drugs for the treatment of diabetes, obesity, and other conditions. Some of its major biologic products include Victoza, Ozempic, and NovoSeven.

Bristol Myers Squibb is a US-based pharmaceutical company that develops and manufactures biologic drugs for the treatment of cancer, cardiovascular diseases, and other conditions. Some of its major biologic products include Opdivo, Yervoy, and Orencia.

Strategic Developments

In December 2020, AstraZeneca announced its acquisition of Alexion Pharmaceuticals for $39 billion. Alexion specializes in the development and manufacture of biologic drugs for the treatment of rare diseases, which will help to expand AstraZeneca's portfolio in this area.

In October 2020, Gilead Sciences announced its acquisition of Immunomedics for $21 billion. Immunomedics specializes in the development and manufacture of biologic drugs for the treatment of cancer, which will help to expand Gilead's portfolio in this area.

In November 2020, Pfizer and BioNTech announced the development of a COVID-19 vaccine, which was authorized for emergency use in the United States and other countries. The vaccine is based on biologic technology, specifically messenger RNA (mRNA) technology.

In January 2021, Sanofi announced its acquisition of Kiadis Pharma, a biotech company that specializes in the development of cell-based immunotherapies for the treatment of cancer. This acquisition will help to expand Sanofi's portfolio in the area of cancer immunotherapy.